Summary

Results from the phase 2 Study Program to Evaluate the Prevention of Ischemia with Direct Xa inhibition [SEPIA-ACS1 TIMI 42; NCT00317395] study provided promising data that otamixaban, an intravenous direct Factor Xa inhibitor, at intermediate doses may be associated with a lower risk of ischemic events with similar bleeding compared with the current standard of care in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) [Sabatine MS et al. Lancet 2009].